Key Recommendations for Asparaginase-Based Treatment Take Center Stage in ASH 2026 AYA Acute Lymphoblastic Leukemia Guidelines

As ongoing research and randomized clinical trials aim to refine treatment strategies and answer lingering questions, the 2026 ASH Guidelines for Frontline Management of Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA) provide recommendations grounded in available evidence to assist in clinical decision-making for this patient population, according to Wendy Stock, MD.¹

“[The guidelines] are not perfect, simply because we haven’t had the ability to have a lot of randomized studies, which strengthens any kind of recommendation,” said Stock, who was a member of a multidisciplinary panel of hematologists, AYA psychosocial care specialists, pharmacists, methodologists, and patient representatives who developed the guidelines. “However, we feel confident that the recommendations we gave are firmly based in evidence with the nuance of discussion given by this broad swath of committed investigators, [all made in an] effort to improve the lives of our AYA [patients] with ALL.”

In the guidelines, which featured 15 recommendations plus additional good-practice statements, pediatric-inspired, asparaginase-containing regimens received a strong recommendation over adult-based approaches as frontline therapy for AYA patients with ALL.² It was also recommended that patients switch to asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze)–based treatment over discontinuation for patients who experience asparaginase-related allergic or hypersensitivity reactions with pegaspargase (Oncaspar). With these pediatric-inspired approaches, the guidelines also recommend the use of prophylactic premedication to prevent hypersensitivity reactions; against the routine use of cryoprecipitate replacement (or fibrinogen concentrate) outside the context of active bleeding; and against the routine use of unfractionated heparin for venous thromboembolism prophylaxis.

Furthermore, the guidelines recommend against the use of allogeneic hematopoietic stem cell transplant (allo-HSCT) as consolidation for patients in first complete remission (CR1) during frontline therapy, with the caveat that certain high-risk subgroups of patients, such as those with persistent minimal residual disease (MRD) positivity, induction failure, and high-risk biologic subsets, may benefit from transplant.

In an interview with OncLive^®, Stock outlined the importance of developing the ASH AYA ALL guidelines and the array of experts who contributed to their formation. She also detailed key recommendations from the guidelines, including the use of asparaginase-based regimens, the role of allo-HSCT after CR1, and the utilization of targeted therapies for this patient population.

Stock is the Anjuli Seth Nayak Professor of Medicine at University of Chicago Medicine and co-leader of the Clinical and Experimental Therapeutics research program at the University of Chicago Medicine Comprehensive Cancer Center in Illinois.

OncLive: In general, what differentiates the AYA ALL patient population from the adult population?

Stock: The AYA population is at an interesting crossroads, in that [these patients] benefit from pediatric-based therapies; that was shown 2 decades ago. However, the problem has been that it’s been tough to administer these regimens to an AYA population. The reason that older adults are not included in these guidelines is that the toxicity of the treatments [essentially] increases with every year of life. [For patients] over the age of 55 years, these AYA guidelines are not useful, because the tolerability of [pediatric-based] regimens is not feasible in that population.

Therefore, our goal was to try to focus on using rigorous systematic reviews [to show] that AYA [patients] benefit from the pediatric[-based] approach, which they do. Survival is better, and every other parameter of assessment is better, [including] event-free and disease-free survival. The challenge is how to best provide those regimens in a way that’s both tolerable and successful for these AYA [patients].

What methods were used to develop these guidelines? What types of specialists were involved in producing these recommendations?

These guidelines are based on rigorous guideline recommendation foundations. There was a methods team that was engaged by ASH to provide the rigorous statistical underpinnings of the guidelines. Members of the group that provided the guidelines [included] investigators from all over the world, including patient advocates, social workers, pharmacists, and clinicians. It was a broad swath of people who provide care, both in academic- and community-based [settings, such as] hematologist oncologists, and other crucial supportive care workers.

Turning to the guidelines, what recommendations were made for the use of asparaginase-based therapies in the AYA ALL patient population?

The guidelines try to address issues of pre-medication, issues of dosing, issues of toxicity management, and alternative approaches for hypersensitivity or anaphylactic reactions. All these are covered to the extent that we could provide firm recommendations, based on the available data.

One of the problems for all these questions that we posed—all of which are relevant to the AYA population—is that the amount of data that has been generated is limited in many cases for a given question. Therefore, recommendations were only given if sufficient data existed to make a recommendation; where we couldn’t provide a firm recommendation, we discussed why, and we give some background information on how those decisions were reached.

What is the current view on the role of allo-HSCT in the management of AYA ALL?

In general, [when] using a pediatric-based regimen, the guidelines [feature] a recommendation to not necessarily proceed to an allo-HSCT in CR1, but that is based largely upon limited data in the sense that there are not randomized studies to completely and accurately assess this question. We do not recommend allo-HSCT in CR1 in general, but caveats include certain maybe high-risk biological patient subsets and the predication that MRD assessment is a crucial factor in determining whether to proceed with transplant in CR1.

What is the current view on the role of targeted therapies in AYA ALL? What additional data and evidence could help parse these strategies for AYA patients with ALL?

The one agent that has been approved in the setting of frontline therapy in terms of antibody-based targeted agents is blinatumomab (Blincyto), which is a CD19[-directed] bispecific T-cell engager. It’s been shown that blinatumomab, in both younger and older adult populations, provides benefit for both event-free and overall survival, and [it] is recommended both in patients who achieve MRD negativity and patients who are persistently MRD positive. Patients [who are persistently MRD positive] after administration of such an agent may then [benefit from] proceeding with an allo-HSCT.

Blinatumomab is now being routinely incorporated, and the guidelines provide recommendations about how, where, and when to potentially administer this targeted antibody. Other targeted antibodies are under review, but there is no specific recommendation for or against any other specific agent, simply because the data do not exist yet to recommend or not to recommend.

As you mentioned, recommendations were made when sufficient evidence was available. What other areas could benefit from additional data to provide sound recommendations?

The biggest questions and focus of the next generation of trials will be how much and what targeted therapies [should be] incorporated into frontline therapy. [Research could help answer] whether the incorporation of these new agents allows us to reduce some of the intensive chemotherapy that we administer and potentially shorten the duration of the therapy and or [decrease] the intensity of the therapy. Those are big questions to which we don’t have answers, but that the next generation of trials will hopefully begin to address those issues.

The guidelines, which are a living document, will be amended and revised as additional information comes forward. Of course, some of the major goals of these guidelines are not only to improve survival in these patients, which is our primary goal, but also to improve quality of life during and following treatment, to avoid long-term toxicities, to avoid infertility, and to provide these patients with the underpinnings to move forward with productive, healthy, and toxicity-free lives.

How can these ASH guidelines supplement other tools to help inform day-to-day decision-making within ALL clinical practice?

The guidelines were issued with a helpful and informative slide set that reviews some of the major recommendations in a case-based format, which might be useful to hematologists. The guidelines, in general, provide a large amount of statistically sound data upon which treatment approaches can be confidently used.

References

1. Stock W. ASH guidelines provide key recommendations for AYA acute lymphoblastic leukemia management: with Wendy Stock, MD. OncLive.com. March 20, 2026. Accessed March 26, 2026. https://www.onclive.com/view/ash-guidelines-provide-key-recommendations-for-aya-acute-lymphoblastic-leukemia-management-with-wendy-stock-md
2. DuVall AS, McNeer J, Cheung MC, et al. ASH 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults. Blood Adv. Published online February 11, 2026. doi:10.1182/bloodadvances.2021006469